Previous 10 | Next 10 |
Point Roberts, WA and Vancouver, BC - May 24, 2021 (Investorideas.com Newswire) Investorideas.com ( www.investorideas.com ), a global investor news source covering Artificial Intelligence (AI) brings you today's edition of The AI Eye - watching stock news, deal tracker and advanceme...
Kiromic Biopharma ([[KRBP]] +4.1%) has submitted an Investigational New Drug ((IND)) to the FDA for Phase 1 trial, ALEXIS-ISO-1, that has the potential to be a universal CAR T-Cell therapy for any solid malignancy that expresses the biomarker Iso-mesothelin. The FDA feedback is expected ...
Kiromic Biopharma, Inc. (Nasdaq: KRBP) is an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics. Kiromic is pleased to announce the identifica...
Kiromic Biopharma ([[KRBP]]) has submitted Investigational New Drug ((IND)) to the FDA for a Phase 1 clinical trial that has the potential to be a universal T-Cell therapy for any solid malignancy that expresses the biomarker PD-L1, with higher efficacy, higher safety, as well as lower manufa...
Kiromic achieves key milestone for this first in human phase 1 clinical trial Kiromic Biopharma, Inc. (Nasdaq: KRBP) Today, Kiromic announces the submission of a novel Investigational New Drug (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical tr...
Kiromic BioPharma (KRBP): Q1 GAAP EPS of -$0.53.Cash and cash equivalents of $7.34MShares +4.78%.Press Release For further details see: Kiromic BioPharma reports Q1 results
Upcoming Investigational New Drug Application Submissions Facility Expansion in Houston, TX Leon Office, Asia, Strategic Marketing Agreement SBA Loan Extinguishment Research Grant Agreement with University of Texas MD Anderson Cancer C...
Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel oncology therapeutics, has announced its technology showcases at the recent American Ass...
Kiromic BioPharma (KRBP): FY GAAP EPS of -$4.42.Cash and equivalents were $10,150,500 as of December 31, 2020, compared to $1,929,100 as of December 31, 2019.Press Release For further details see: Kiromic BioPharma reports FY results
Completion of $15 million IPO Longwood University Licensing Agreement of chPD1 Two IND Application Filings for chPD1, Isomesothelin, Allogeneic Gamma Delta, CAR-T Therapies GMP Facility Completion, Certification Kiromic BioPharma (NASDAQ: ...
News, Short Squeeze, Breakout and More Instantly...
Kiromic BioPharma Inc. Company Name:
KRBP Stock Symbol:
OTCMKTS Market:
Kiromic BioPharma Inc. Website:
Enrollment in the Expansion Phase Expected to Commence in September Deltacel Safety Confirmed at Day 30 in Trial’s Fifth Patient; Efficacy Results on this Patient Expected in August Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company...
Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial’s Second Cohort Expected in July Kiromic BioPharma, Inc. ...
Favorable Follow-up Findings Include Stable Disease and a 13% Decrease in Tumor Size Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase ...